Davar Altafi

Davar Altafi

Auto-generated profile, based on publicly available information

Davar Altafi

From the School of Nutrition and Food Sciences (R.H., M.M), Tabriz University of Medical Sciences; Road Traffic Injury Research Center (M.A.-J), Tabriz University of Medical Sciences; Ardabil Province (D.A.); Department of Genetics (S.S.H.-A.), School of Medicine, Ardabil University of Medical Sciences; Department of Biochemistry and Diet Therapy (S.R.-A.), School of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Iran

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Neurology Genetics
Verified
Journal Article
Open access
PDF file
RHReza Hashemi
Reza Hashemi
MMMohammad Morshedi
Mohammad Morshedi
MJMohammad Asghari Jafarabadi
Mohammad Asghari Jafarabadi
DADavar Altafi
Davar Altafi
SHSeyed Saeed Hosseini-Asl
Seyed Saeed Hosseini-Asl
SASeyedRafie ArefHosseini
SeyedRafie ArefHosseini
Objective To assess the effects of dietary vitamin D3 on proinflammatory (interleukin-17A [IL-17A] and IL-6) and anti-inflammatory (IL-10) cytokines. Methods Our study was conducted on 75 participants who were divided into 3 groups: multiple sclerosis participants (MSPs, n = 25), first-degree relative participants (FDRPs, n = 25), and healthy participants (HPs, n = 25). All groups received 50,000 IU vitamin D3/wk for 8 weeks. Serum 25-(OH) vitamin D3 levels and messenger RNA (mRNA) expression levels of ILs were determined using electrochemiluminescence assay and real-time PCR, respectively. Results Vitamin D3 affected the levels of IL-17A, IL-10, and IL-6 among the 3 groups (p < 0.001 for all). Levels of IL-17A (MSPs: fold change [FC] = 5.9, p = 0.014; FDRPs: FC = 5.2, p = 0.006; HPs: FC = 4.2, p = 0.012) and IL-6 (MSPs: FC = 5.6, p = 0.003; FDRPs: FC = 5.5, p = 0.002; HPs: FC = 5.1, p < 0.001) were downregulated after vitamin D3 treatment. In addition, levels of IL-10 (MSPs: FC = 6.2, p = 0.005; FDRPs: FC = 4.6, p < 0.001; HPs: FC = 5.2, p < 0.001) were upregulated after 8 weeks. Conclusions Although supplementation with vitamin D3 reduced the mRNA expression levels of IL-17A and IL-6, it increased the mRNA expression level of IL-10 in all groups. However, these effects were more considerable in the MSP group than in the other groups. Of interest, in a deficiency state of serum vitamin D3, IL-17A expression had a positive feedback effect on the expression of IL-6. Conversely, in the sufficient state, IL-10 expression had a negative feedback effect on the expression of IL-17A and IL-6.

5 May 2014 in Iranian Red Crescent Medical Journal
Verified
Journal Article
Open access
PDF file
HAHormoz Ayromlou
Hormoz Ayromlou
HSHassan Soleimanpour
Hassan Soleimanpour
MFMehdi Farhoudi
Mehdi Farhoudi
ATAliakbar Taheraghdam
Aliakbar Taheraghdam
ESElyar Sadeghi-Hokmabadi
Elyar Sadeghi-Hokmabadi
DADavar Altafi
Davar Altafi
Background: Intravenous thrombolysis is an approved treatment method for patients with acute ischemic stroke (AIS) and is recommended by multiple guidelines. However, it seems that it is less frequently used in the developing countries compared to the developed countries. Objectives: The purpose of this study was to estimate the percentage of patients with AIS, eligible for intravenous thrombolytic therapy, at the main referral center in Northwest Iran and to determine the main barriers for implementation of this method. Patients and Methods: Over one year, 647 patients who were admitted to the emergency department and met the Cincinnati Stroke Scale were enrolled into the study. The center to which patients were admitted, is a tertiary university hospital that has the required infrastructure for thrombolytic therapy in AIS. Factors recorded were neurological examinations and time between onset of symptoms and hospital arrival, hospital arrival and performance of brain computed tomography (CT) scanning, and hospital arrival to complete the investigations. Patients eligible for intravenous thrombolytic therapy were identified according to the American Heart Association (AHA) guidelines. Results: Mean time interval between hospital arrival and completion of brain CT scanning was 91 minutes (range: 20–378 minutes) and mean time from hospital arrival to completion of investigations was 150 minutes (range: 30–540 minutes). A total of 159 (31.3%) patients arrived at hospital within 3 hours of the onset of symptoms (early enough for intravenous thrombolytic therapy). However, 81.7% (130/159) of these patients missed thrombolytic therapy due to delayed performance of brain CT scanning and laboratory tests and 38.3% (61/159) had contraindications. The remaining 16 patients (10% of those who arrived within 3 hours and 3.1% of all cases) were eligible for thrombolytic therapy. Conclusions: The major barriers for thrombolytic therapy for patients with AIS in this setting were delays in the provision of in-hospital services, like initial patient assessment, CT scans or laboratory studies. These results were in contrast with previous reports. Keywords: Stroke; Thrombolytic Therapy; Developing Country; Eligibility Determination

1 January 2014 in International Surgery Journal
Verified
Journal Article
Closed access
PDF file
BSBehzad Skandaroghli
Behzad Skandaroghli
FAFirouz Amani
Firouz Amani
DADavar Altafi
Davar Altafi
AMAzari Majid
Azari Majid
Background: Outdated Lumbar discopathy is a deterioration of the intervertebral disc of the lumbar spine level. Spondylosis is a process that affects the entire axial skeleton and includes a stage of degenerative changes which occur at the cellular and biochemical level. Due to high occurrence rate of back discs over the society and its importance. The aim of this study was determine symptom and indications for surgery in patients with lumbar discopathy. Methods: This is a descriptive-analytical study that has been done on 90 patient’s candidate for lumbar discopathy surgery between 2009 and 2012. Their general condition and level of satisfaction after surgery were evaluated by phone calls of the patients Results: From all 90 patients, 55 (66.1%) were men and 35 (39.9%) were women with sex ratio l to 1.6. From all patients, 41 (45.6%) were self- employed and worker and most of them with 46.7% were hospitalized for 4 days. Indications of neurologic deficit - Limits daily activations - Intractable pain medication altogether with 42.3% were the most. 84 (93.3%) patients were recovered respect to before surgery. 9 patients (10%) had recurrence of symptoms. Indications of intractable pain medication with 36 (40%) patients had a considerable amount. L4- L5 involvement level with 44 cases (48.9%) respect to other levels has been the most. Conclusions: Based on the results, the most indications which patients had for surgery was intractable pain medication which in most of them patients were recovered and highly satisfied. According to the results, patients who have intractable pain and other patients with different indications could benefit from a surgical treatment.

22 August 2018 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
RMReza Mohammadian
Reza Mohammadian
ESEhsan Sharifipour
Ehsan Sharifipour
ATAliakbar Taheraghdam
Aliakbar Taheraghdam
RMReza Mansourizadeh
Reza Mansourizadeh
DADavar Altafi
Davar Altafi
SGSamad E.J. Golzari
Samad E.J. Golzari